Structural details of a Class B GPCR-arrestin complex revealed by genetically encoded crosslinkers in

Genetic variants of G-protein coupled receptors associated with pubertal disorders.

Publication in Nature Scientific Reports on Novel Anticancer Therapy An extraordinary opportunity to generate

receptor, which binds the primary messenger, (2) a transducer that requires GTP, and (3) an amplifier that generates Interaction of G-Protein βγ Complex with Chromatin Modulates GPCR- Dependent Gene Regulation.

Genetic code expansion to enable site-specific bioorthogonal labeling of functional G protein-coupled

are cleaved at the GPCR Proteolysis Site motif of the GAIN domain through an auto-catalysis process generating

Chemokine-CKR interaction follows a common pattern which is generally described by the classic “two-site

In view of this, three possibilities are conceivable: (i) there are no generalizable GPCR conformations

December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq

March 2022 " Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage

August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage

Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders "Geneva

July 2022 " Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics

Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva

Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study " Geneva

blind assessments of ligand pose quality and affinity prediction have thus far not provided broadly generalizable

Companies of Johnson & Johnson, Inc. has completed Phase 1 studies in Japan with JNJ-40411813 (ADX71149) " Geneva